Abstract
A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may also lead to dose reduction of chemotherapy and/or treatment delays in both chemotherapy and radiation therapy, diminishing the efficacy of therapy in the curative setting. In this setting, the use of hematopoietic growth factors may thus be beneficial.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anemia / drug therapy
-
Anemia / etiology
-
Antineoplastic Agents / adverse effects*
-
Bone Marrow / drug effects*
-
Bone Marrow / radiation effects
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / radiotherapy
-
Colony-Stimulating Factors / pharmacology
-
Colony-Stimulating Factors / therapeutic use*
-
Combined Modality Therapy
-
Hematologic Diseases / drug therapy*
-
Hematologic Diseases / etiology*
-
Hematologic Diseases / prevention & control
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / radiotherapy
-
Neutropenia / drug therapy
-
Neutropenia / etiology
-
Radiation Injuries / drug therapy
-
Radiation Injuries / prevention & control
-
Radiotherapy / adverse effects
-
Thrombocytopenia / drug therapy
-
Thrombocytopenia / etiology
Substances
-
Antineoplastic Agents
-
Colony-Stimulating Factors